Licaminlimab

Oculis has successfully enrolled over 800 patients across 119 global sites in its DIAMOND Phase 3 trials evaluating OCS-01, the first-ever topical eye drop treatment for diabetic macular edema.

Oculis announced the expansion of Privosegtor (OCS-05) development beyond acute optic neuritis to include non-arteritic anterior ischemic optic neuritis (NAION) and acute relapses in multiple sclerosis patients.

Oculis' OCS-05 demonstrates significant neuroprotective effects in acute optic neuritis patients, showing preserved retinal ganglion cells and reduced multiple sclerosis relapses in Phase 2 ACUITY trial.

Ocular Therapeutix's SOL-R trial for AXPAXLI in wet AMD has enrolled 311 subjects, showing significant progress in the registrational program.

Oculis reports significant progress in its product pipeline, notably in the OCS-01 Phase 3 DIAMOND program for diabetic macular edema (DME) and the OCS-05 Phase 2 ACUITY trial for acute optic neuritis (AON).